Cyclic Peptide Antibacterial Against MRSA VRSA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibiotics are ineffective against antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA), posing a significant threat to global health due to widespread resistance.
Innovation Solution
A novel cyclic peptide compound, isolated from Staphylococcus lugdunensis and characterized by specific amino acid configurations, exhibits strong antimicrobial activity against resistant bacteria, including MRSA and VRSA, and can be used in pharmaceutical compositions for treatment and prophylaxis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then treatment is effective against susceptible bacteria, but antibiotics become ineffective against antibiotic-resistant bacteria such as MRSA and VRSA
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of cyclic peptides through varying amino acid sequences, ring sizes, and side chain configurations to achieve broad-spectrum activity against antibiotic-resistant bacteria. The core structure with specific variable positions allows optimization of bacterial cell wall binding affinity while maintaining stability against resistance mechanisms.
Solution Approach 2:
The invention utilizes composite materials by combining multiple amino acid residues with specific properties (hydrophobic, hydrophilic, aromatic, aliphatic) within a single cyclic peptide molecule. This composite structure enables simultaneous interaction with different components of the bacterial cell wall, enhancing effectiveness against diverse resistant strains including MRSA and VRSA.
2Reliability
If new antibiotics are developed to treat resistant bacteria, then effectiveness against resistant strains improves, but development time and cost increase
Solution Approach 1:
The patent applies segmentation by dividing the cyclic peptide into a core structure and variable side chains. This modular approach allows systematic exploration of structure-activity relationships by modifying specific positions while maintaining the active core, thereby accelerating identification of effective compounds against resistant bacteria without requiring complete de novo development.
Solution Approach 2:
The invention achieves universality through a core cyclic peptide structure that can perform multiple functions by incorporating different amino acid combinations. This single platform can target various bacterial species and resistance mechanisms, reducing the need for separate drug development programs for different resistant strains.
3Reliability
If cyclic peptide structure is optimized for antimicrobial activity, then bactericidal effectiveness increases, but selectivity against host cells may decrease
Solution Approach 1:
The patent applies local quality by assigning specific functional roles to different regions of the cyclic peptide. The core structure provides membrane interaction capability, while specifically positioned amino acid side chains confer selectivity for bacterial cell wall components. This localized functional distribution enhances bactericidal activity while minimizing off-target effects on host cells.
Data Source
AI summary
The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being.